Goldfinch Bio, Inc.
5
0
0
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
60.0%
3 terminated/withdrawn out of 5 trials
40.0%
-46.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Role: lead
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
Role: lead
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
Role: lead
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
Role: lead
FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects
Role: lead
All 5 trials loaded